Injectable contraception: the USA perspective.
D000569:Americas; D001943:Breast Neoplasms; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D019049:Developed Countries; D004194:Disease; D016889:Endometrial Neoplasms; D005069:Evaluation Studies as Topic; D005193:Family Planning Services; D006077:Government Agencies; D006297:Health Services Accessibility; D007267:Injections; D017258:Medroxyprogesterone Acetate; D008599:Menstruation Disturbances; D009369:Neoplasms; D009640:Norethindrone; D009656:North America; D009938:Organizations; D014481:United States; D014486:United States Food and Drug Administration; D014492:United States Public Health Service
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone
Americas; Breast Cancer; Cancer; Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Availability; Contraceptive Effectiveness; Contraceptive Methods--side effects; Critique; Depo-provera--side effects; Developed Countries; Diseases; Endometrial Cancer; Family Planning; Government Agencies; Injectables--side effects; Medroxyprogesterone Acetate--side effects; Menstruation Disorders; Neoplasms; Norethindrone; Norethindrone Enanthate; North America; Northern America; Organizations; Reversibility; United States; Usfda; Usphs